Literature DB >> 18302817

Revising the tuberculosis recording and reporting information system.

P-Y Norval1, E Heldal, R L'Herminez, K Laserson, A Godfrey.   

Abstract

OBJECTIVE: The tuberculosis recording and reporting information system (TB R&R), one of the five pillars of the DOTS strategy, has undergone a revision to comply with the new elements of the Stop TB Strategy and to ensure standardisation of essential TB information.
DESIGN: An expert group on TB R&R, including the main technical partners, held a series of consultations with the Stop TB Working Groups and countries. Draft revised forms were field tested by countries with the participation of technical partners. A survey was conducted by the World Health Organization (WHO) in 105 countries. RESULT: The main changes in the TB R&R are the inclusion of TB-HIV activities (the leading reason for change at the country level), smear examinations and culture for settings performing this test routinely and the management of patient drug kits. The revised forms help monitor contributions from all care providers and community workers. The package of forms is presented in three sets: 1) essential data, 2) setting with routine culture and 3) additional data.
CONCLUSION: The revised R&R forms were endorsed by the WHO, the KNCV Tuberculosis Foundation, the International Union Against Tuberculosis and Lung Disease and the US Centers for Disease Control and Prevention in 2007. They are now available in English, French and Spanish, and are adopted in most countries.

Entities:  

Mesh:

Year:  2008        PMID: 18302817

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  1 in total

1.  Childhood tuberculosis deskguide and monitoring: an intervention to improve case management in Pakistan.

Authors:  Nauman Safdar; Sven Gudmund Hinderaker; Noor Ahmed Baloch; Donald A Enarson; Muhammad Amir Khan; Odd Morkve
Journal:  BMC Health Serv Res       Date:  2011-08-10       Impact factor: 2.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.